Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366541 | 0.84 | CCR3 (0.46) | ALDH1A1OPRL1OPRK1TACR1SLC6A4 | |
| SCHEMBL5372806 | 0.80 | SIGMAR1 (0.56) | ALDH1A1TACR1SLC6A4CHRM2CHRM3 | |
| SCHEMBL14416999 | 0.78 | OPRM1 (0.41) | ALDH1A1KDM1AOPRM1OPRL1OPRD1 | |
| SCHEMBL5363132 | 0.77 | OPRM1 (0.50) | ALDH1A1KDM1AOPRM1OPRL1OPRD1 | |
| SCHEMBL5369324 | 0.72 | TACR1 (0.38) | OPRM1OPRL1TACR1SLC6A4CHRM2 | |
| SCHEMBL5357734 | 0.72 | CHRM5 (0.41) | ALDH1A1OPRM1OPRL1TACR1SLC6A4 | |
| SCHEMBL5369342 | 0.72 | SLC6A4 (0.38) | OPRM1OPRL1TACR1SLC6A4SIGMAR1 | |
| SCHEMBL5357598 | 0.71 | TACR1 (0.54) | TACR1SLC6A4 | |
| SCHEMBL5362767 | 0.71 | MEN1 (0.50) | ALDH1A1KDM1AOPRM1OPRD1OPRK1 | |
| SCHEMBL5364935 | 0.71 | OPRM1 (0.43) | ALDH1A1KDM1AOPRM1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HOEMANN MICHAEL Z (US) | 2004-07-22 | — | — | US | disclosed |
| US-6656953-B2 | Ligands for receptors such as dopamine, serotonin, or norepinephrine transporters; broad uses claimed, such as pain reliever and antidepressant | SEPRACOR INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | SEPRACOR INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002046156-A2 | 4,4-DISUBSTITUTED PIPERIDINES FOR USE AS DOPAMINE, SEROTONIN AND NOREPINEPHRINE LIGANDS | SEPRACOR, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | HTR2C, HTR5A, OPRL1 | ALDH1A1 274/4885KDM1A 3773/4885OPRM1 28/4885 |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | ALDH1A1 314/4885KDM1A 3470/4885OPRM1 25/4885 |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | ALDH1A1 314/4885KDM1A 3470/4885OPRM1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.